Document is current
Any future updates will be listed below
-
Authors
Schiroli, Giulia https://orcid.org/0000-0002-9812-8728
Kartha, Vinay
Duarte, Fabiana M. https://orcid.org/0000-0002-1261-4929
Kristiansen, Trine A.
Mayerhofer, Christina
Shrestha, Rojesh
Earl, Andrew https://orcid.org/0000-0002-5732-954X
Hu, Yan
Tay, Tristan
Rhee, Catherine
Buenrostro, Jason D. https://orcid.org/0000-0001-9958-3987
Scadden, David T. https://orcid.org/0000-0001-9821-7133
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (P01HL131477-03)
MDS Edward P. Evans Foundation
- License Information
-
More Information
Article History
Received: 17 June 2023
Accepted: 30 April 2024
First Online: 21 May 2024
Competing interests
: G.S. is currently an employee of Tessera Therapeutics. D.T.S. is a founder, director and stockholder of Magenta Therapeutics, Clear Creek Bio, and LifeVaultBio. He is a director of Agios Pharmaceuticals, Editas Medicine and Sonata Therapeutics and a founder and stockholder of Fate Therapeutics and Garuda Therapeutics. He is a consultant for VCanBio and SAB member of Simcere Pharmaceuticals. J.D.B. is a SAB member of Camp4 and seqWell. Other authors declare no competing interests.
